Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.

Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E

Diabetes, obesity & metabolism20 Jun 2017Cited by 189 (Europe PMC)

PMID28244632DOI10.1111/dom.12926PepBankPUB-28244632

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) did not significantly change pancreatitis incidence versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including liraglutide) found no clear change in pancreatitis.
Peptide
Liraglutide
Outcome
No significant changePancreatitis incidence
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Gastrointestinal
Measurements
MH-OR
0.93 odds ratio
pancreatitis
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2824463201
02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) did not significantly change pancreatic cancer incidence versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including liraglutide) found no clear change in pancreatic cancer.
Peptide
Liraglutide
Outcome
No significant changePancreatic cancer incidence
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Cancer
Measurements
MH-OR
0.94 odds ratio
pancreatic cancer
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2824463202
03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) significantly increased the risk of cholelithiasis versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including liraglutide) found more gallstone disease than with other treatments.
Peptide
Liraglutide
Outcome
IncreaseCholelithiasis risk
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Gastrointestinal
Measurements
MH-OR
1.3 odds ratio
cholelithiasis
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2824463203
04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) did not significantly change pancreatitis incidence versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including semaglutide) found no clear change in pancreatitis.
Peptide
Semaglutide
Outcome
No significant changePancreatitis incidence
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Gastrointestinal
Measurements
MH-OR
0.93 odds ratio
pancreatitis
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2824463204
05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) did not significantly change pancreatic cancer incidence versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including semaglutide) found no clear change in pancreatic cancer.
Peptide
Semaglutide
Outcome
No significant changePancreatic cancer incidence
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Cancer
Measurements
MH-OR
0.94 odds ratio
pancreatic cancer
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2824463205
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) significantly increased the risk of cholelithiasis versus comparators.
In plain wordsIn adults with type 2 diabetes, trials of GLP-1 drugs as a group (including semaglutide) found more gallstone disease than with other treatments.
Peptide
Semaglutide
Outcome
IncreaseCholelithiasis risk
Study
n: not reported in source
Comparator
Placebo or non-GLP-1 receptor agonist drugs
Outcome group
Adverse events · Gastrointestinal
Measurements
MH-OR
1.3 odds ratio
cholelithiasis
Source sentences
Summary
The incidence of pancreatitis and pancreatic cancer with GLP1-RA was not significantly different from that observed in comparator arms (MH-OR [95% CI] 0.93 [0.65-1.34], P = .71, and 0.94 [0.52-1.70], P = .84, respectively), whereas, a significantly increased risk of cholelithiasis (MH-OR [95% CI] 1.…
1 context sentence(design, population, supporting numbers)
Summary · context
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide or semaglutide) was performed, collecting all randomized clinical trials with a duration >11 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 receptor agonist with placebo…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2824463206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07617155

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

Peking Union Medical College Hospitaln = 396est. Sept 2026 to est. Dec 2028

Hypertriglyceridemia Induced Acute Pancreatitis · Recurrent Acute Pancreatitis · Pancreatitis Relapsing · Hypertriglyceridemia

Trial page ClinicalTrials.govUpdated 1 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 5Current
27 Oct 2026, 16:36 UTC
The same notice was added 2 times, first on 21 Oct 2026, 18:59 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC